Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Imatinib mesylate was initially approved for chronic myeloid leukemia. It has also been used against gastrointestinal cancer and melanoma. What are the implications of broadening the application of this targeted cancer drug for the way that cancers are diagnosed and classified, and what will the impact be on clinical trial design? Are we getting closer to the end of tumor-typing by location?
Imatinib mesylate was initially approved for chronic myeloid leukemia. It has also been used against gastrointestinal cancer and melanoma. What are the implications of broadening the application of this targeted cancer drug for the way that cancers are diagnosed and classified, and what will the impact be on clinical trial design? Are we getting closer to the end of tumor-typing by location?
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
Diagnosis and Management of Metastatic PDAC
TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management
Partnering with Patients: Building Effective Communication and Support in HF Care
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Stay current with the best on medical education
